Generics drive Dr Reddy's Q2 revenues up 14%
This article was originally published in Scrip
Dr Reddy's Laboratories has reported a 14% increase in consolidated revenues to Rs18.4 billion ($382 million) for the second quarter ended September 30th, driven by growth in the generics business.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.